Pfizer Protocol C4391022: An interventional, open-label, randomized, multicenter phase 2 study of PF-07220060 plus fulvestrant compared to investigator’s choice of therapy in participants at least 18 years of age with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer whose disease progressed after prior CDK4/6 inhibitor-based therapy (FOURLIGHT-1)